Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection

Jeffrey Seow(King's College London), Carl Graham(King's College London), Blair Merrick(Guy's and St Thomas' NHS Foundation Trust), Sam Acors(King's College London), Kathryn J. A. Steel(King's College London), Oliver Hemmings(King's College London), Aoife O’Bryne(King's College London), Neophytos Kouphou(King's College London), Suzanne Pickering(King's College London), Rui Pedro Galão(King's College London), Gilberto Betancor(King's College London), Harry Wilson(King's College London), Adrian W. Signell(King's College London), Helena Winstone(King's College London), Claire Kerridge(King's College London), Nigel Temperton(Medway School of Pharmacy), Luke B. Snell(Guy's and St Thomas' NHS Foundation Trust), Karen Bisnauthsing(Guy's and St Thomas' NHS Foundation Trust), Amelia Moore(Guy's and St Thomas' NHS Foundation Trust), Adrian J. Green(Guy's and St Thomas' NHS Foundation Trust), Lauren Martinez(Guy's and St Thomas' NHS Foundation Trust), Brielle Stokes(Guy's and St Thomas' NHS Foundation Trust), Johanna Honey(Guy's and St Thomas' NHS Foundation Trust), Alba Izquierdo-Barras(Guy's and St Thomas' NHS Foundation Trust), Gill Arbane(St Thomas' Hospital), Amita Patel(Guy's and St Thomas' NHS Foundation Trust), Lorcan O’Connell(Guy's and St Thomas' NHS Foundation Trust), Geraldine O’Hara(Guy's and St Thomas' NHS Foundation Trust), Eithne MacMahon(Guy's and St Thomas' NHS Foundation Trust), Sam Douthwaite(Guy's and St Thomas' NHS Foundation Trust), Gaia Nebbia(Guy's and St Thomas' NHS Foundation Trust), Rahul Batra(Guy's and St Thomas' NHS Foundation Trust), Rocío T. Martínez-Nuñez(King's College London), Jonathan D. Edgeworth(King's College London), Stuart J. D. Neil(King's College London), Michael H. Malim(King's College London), Katie J. Doores(King's College London)
medRxiv
July 11, 2020
Cited by 364Open Access
Full Text

Abstract

Abstract Antibody (Ab) responses to SARS-CoV-2 can be detected in most infected individuals 10-15 days following the onset of COVID-19 symptoms. However, due to the recent emergence of this virus in the human population it is not yet known how long these Ab responses will be maintained or whether they will provide protection from re-infection. Using sequential serum samples collected up to 94 days post onset of symptoms (POS) from 65 RT-qPCR confirmed SARS-CoV-2-infected individuals, we show seroconversion in >95% of cases and neutralizing antibody (nAb) responses when sampled beyond 8 days POS. We demonstrate that the magnitude of the nAb response is dependent upon the disease severity, but this does not affect the kinetics of the nAb response. Declining nAb titres were observed during the follow up period. Whilst some individuals with high peak ID 50 (>10,000) maintained titres >1,000 at >60 days POS, some with lower peak ID 50 had titres approaching baseline within the follow up period. A similar decline in nAb titres was also observed in a cohort of seropositive healthcare workers from Guy’s and St Thomas’ Hospitals. We suggest that this transient nAb response is a feature shared by both a SARS-CoV-2 infection that causes low disease severity and the circulating seasonal coronaviruses that are associated with common colds. This study has important implications when considering widespread serological testing, Ab protection against re-infection with SARS-CoV-2 and the durability of vaccine protection.


Related Papers

No related papers found

Powered by citation graph analysis